#oral medication

AstraZeneca's once-daily oral GLP-1 receptor agonist demonstrated positive results in Phase 2 obesity and diabetes studies, though analysts caution it's too early to compare with other oral treatments.

Structure Therapeutics reports encouraging Phase 2 results for its oral GLP-1 receptor agonist, advancing a pill-form alternative to injectable weight-loss and diabetes drugs.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.